Shiloh
Editor, Senior Moderator
Source: https://www.cidrap.umn.edu/news-perspective/2020/05/news-scan-may-28-2020
News Scan for May 28, 2020
Inhaled antibiotic for cystic fibrosis infections; Antibiotics in Australian nursing homes
Filed Under:
Antimicrobial Stewardship
CARB-X to fund antibiotic for cystic fibrosis-related lung infections
CARB-X today announced an award of up to $6.1 million to support the preclinical development of an inhaled antibiotic to treat cystic fibrosis (CF)-related pulmonary infections
The funding will help Microbion Corporation of Bozeman, Montana, develop pravibismane, a novel anti-infective that has shown potent activity in laboratory tests against antibiotic-resistant pathogens such as multidrug-resistant Pseudomonas aeruginosa, and the biofilms produced by these pathogens. People with CF are susceptible to chronic bacterial infections caused in part by thick mucus in their lungs that traps bacteria pathogens, which in turn develop protective layers of biofilm that make treatment difficult.
Microbion could receive an additional $5.4 million from CARB-X (the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) if certain project milestones are met. The company also received $5.6 million from the Cystic Fibrosis Foundation.
"Beyond their investment, these organizations' expertise in antibiotic-resistant infections, particularly those associated with CF, will prove valuable to advancing our technology as part of a much-needed solution to address the chronic and intractable infections that are a hallmark of CF," Microbion Chairman Karim Lalji said in a CARB-X press release.
May 28 CARB-X press release
Study: Antibiotic use rising in Australian nursing homes
A nationwide study of antibiotic prescribing in Australian nursing homes found marked increases in use and consumption between 2005 and 2016, researchers reported yesterday in Clinical Infectious Diseases.
Their analysis, which included 502,752 residents and 3,218 nursing homes, covered 424.9 million resident days. Antibiotics were prescribed 5,608,126 million times over the 10-year study period, 88% of them for oral use. The most commonly prescribed antibiotics were cefalexin, amoxicillin-clavulanic acid, and trimethoprim.
Annual prevalence rose from 63.8% to 70.3%, with a 39% relative increase in total consumption of systemic antibiotics. Over the study period, use increased from 67.6 to 93.8 defined daily doses (DDDs) per 1,000 resident days, with an average annual increase of 2.8 DDDs per 1,000 resident days.
The group said the increasingly widespread use of antibiotics in Australian nursing homes is concerning and underscores the need for stronger stewardship efforts in those settings.
May 27 Clin Infect Dis abstract
News Scan for May 28, 2020
Inhaled antibiotic for cystic fibrosis infections; Antibiotics in Australian nursing homes
Filed Under:
Antimicrobial Stewardship
CARB-X to fund antibiotic for cystic fibrosis-related lung infections
CARB-X today announced an award of up to $6.1 million to support the preclinical development of an inhaled antibiotic to treat cystic fibrosis (CF)-related pulmonary infections
The funding will help Microbion Corporation of Bozeman, Montana, develop pravibismane, a novel anti-infective that has shown potent activity in laboratory tests against antibiotic-resistant pathogens such as multidrug-resistant Pseudomonas aeruginosa, and the biofilms produced by these pathogens. People with CF are susceptible to chronic bacterial infections caused in part by thick mucus in their lungs that traps bacteria pathogens, which in turn develop protective layers of biofilm that make treatment difficult.
Microbion could receive an additional $5.4 million from CARB-X (the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) if certain project milestones are met. The company also received $5.6 million from the Cystic Fibrosis Foundation.
"Beyond their investment, these organizations' expertise in antibiotic-resistant infections, particularly those associated with CF, will prove valuable to advancing our technology as part of a much-needed solution to address the chronic and intractable infections that are a hallmark of CF," Microbion Chairman Karim Lalji said in a CARB-X press release.
May 28 CARB-X press release
Study: Antibiotic use rising in Australian nursing homes
A nationwide study of antibiotic prescribing in Australian nursing homes found marked increases in use and consumption between 2005 and 2016, researchers reported yesterday in Clinical Infectious Diseases.
Their analysis, which included 502,752 residents and 3,218 nursing homes, covered 424.9 million resident days. Antibiotics were prescribed 5,608,126 million times over the 10-year study period, 88% of them for oral use. The most commonly prescribed antibiotics were cefalexin, amoxicillin-clavulanic acid, and trimethoprim.
Annual prevalence rose from 63.8% to 70.3%, with a 39% relative increase in total consumption of systemic antibiotics. Over the study period, use increased from 67.6 to 93.8 defined daily doses (DDDs) per 1,000 resident days, with an average annual increase of 2.8 DDDs per 1,000 resident days.
The group said the increasingly widespread use of antibiotics in Australian nursing homes is concerning and underscores the need for stronger stewardship efforts in those settings.
May 27 Clin Infect Dis abstract